Targeted protein degradation with small molecules for cancer immunotherapy
Authors:
- Zichao YangZYZichao Yang
- Jianwei XuJXJianwei Xu
- Xixiang YangXYXixiang Yang
- Jianjun ChenJCJianjun Chen
Open Access
- 22 April 2025
- journal article
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 20 (4)
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82173668, 82373706)
This publication has 170 references indexed in Scilit:
- PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applicationsJournal of Molecular Medicine, 2024
- Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- The role of transforming growth factor-β (TGF-β) in the formation of exhausted CD8 + T cellsClinical and Experimental Medicine, 2024
- Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated AntibodiesAngewandte Chemie International Edition, 2024
- BCL-2 protein family: attractive targets for cancer therapyApoptosis, 2022
- A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands, New Drug Leads and PROTACsAngewandte Chemie International Edition, 2022
- LYTACs: An Emerging Tool for the Degradation of Non‐Cytosolic ProteinsChemMedChem, 2021
- Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti‐tumor immunity in non‐small cell lung cancerDrug Development Research, 2020
- Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myelomaJournal of Cellular Physiology, 2020
- Targeted Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful Chemical Genetic ToolChemBioChem, 2007